“The first Alzheimer’s drug will change the history of the disease”

The first anti-Alzheimer’s drug approved by the American FDA, Aducanumab, on the one hand marks a historic stage in the fight against this condition that destroys the lives of many people and their families, but on the other hand it has many aspects that should be kept in mind. consideration so that, despite justified optimism, there is no risk of pernicious illusions. The drug has had a troubled history, with a trial that was first interrupted due to inconclusive results in March 2019 and then resumed in October of the same year.